Prospective, Multicenter, Randomized, Double-blind, Parallel-group, Dose-response Study of Three Doses Xeomin (incobotulinumtoxinA, NT 201) for the Treatment of Lower Limb Spasticity in Children and Adolescents (Age 2 - 17 Years) With Cerebral Palsy

Trial Profile

Prospective, Multicenter, Randomized, Double-blind, Parallel-group, Dose-response Study of Three Doses Xeomin (incobotulinumtoxinA, NT 201) for the Treatment of Lower Limb Spasticity in Children and Adolescents (Age 2 - 17 Years) With Cerebral Palsy

Completed
Phase of Trial: Phase III

Latest Information Update: 30 May 2017

At a glance

  • Drugs Botulinum toxin A (Primary)
  • Indications Muscle spasticity
  • Focus Registrational; Therapeutic Use
  • Acronyms TIM
  • Sponsors Merz Pharmaceuticals GmbH
  • Most Recent Events

    • 26 Jul 2016 Status changed from active, no longer recruiting to completed.
    • 09 Jun 2016 The trial was completed in Germany (end date:2016-05-11).
    • 18 May 2016 This trial is completed in Austria, Czech Republic and Spain, according to the European Clinical Trials Database.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top